For the past two decades, multiple studies using gain-of-function genetic approaches [67], loss-of-function genetic approaches [68,69,70] and pharmacological approaches, such as sRAGE, anti-RAGE antibodies, DNA aptamers against AGEs or RAGE, and low-molecular weight heparin [68,69,71,72,73,74] were employed to illustrate roles for RAGE in murine models of type 1 and type 2 diabetic kidney disease (DKD). The gene discussed is AGER; the disease is diabetic kidney disease.